Shanghai Junshi Biosciences to List GDRs on Swiss Exchange, Raising RMB 3.4 Billion
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) is preparing to issue 68,292,200...
CStone Pharmaceuticals Presents Ayvakit Data for Advanced GIST at ASCO 2023
China-based CStone Pharmaceuticals (HKG: 2616) announced that new data from a post hoc analysis of...
Hansoh Pharmaceutical Gets NMPA Approval for HS-20117 Bispecific Antibody Clinical Study
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced receiving approval from the National...
Chinese Pharma Companies Update Pipelines at ASCO 2023 Annual Meeting
A number of Chinese pharmaceutical companies have shared updates on their pipeline developments at the...
Sinovac Biotech Partners with Bogota to Establish BogotáBio for Vaccine Production
China-based Sinovac Biotech Ltd (NASDAQ: SVA) has announced a strategic partnership with Bogota, the capital...
Longreach Group Puts Quasar Medical on the Block, Attracting Major Bidders
Private equity firm Longreach Group, which specializes in the Asian market, is in the process...
Gracell Biotechnologies’ GC012F Showcases Positive Data at ASCO Annual Meeting
Suzhou-based biotech firm Gracell Biotechnologies Inc., (Nasdaq: GRCL) has announced positive data for its pipeline...
Biosyngen’s BRG01 Earns Orphan Drug Designation from US FDA for Nasopharyngeal Carcinoma
Biosyngen, a leading cell therapy developer based in Guangzhou, has announced that it has received...
NMPA Clears Medtronic’s Corindus for Marketing of Advanced Coronary Surgery Systems
The National Medical Products Administration (NMPA) has granted marketing approval for the “coronary artery interventional...
NMPA Grants Market Approval for Lanzhou Kejin Taiji’s Carbon Ion Therapy System
The National Medical Products Administration (NMPA) in China has issued market approval to Lanzhou Kejin...
HighTide Therapeutics Inc. Plans Hong Kong IPO to Fund Clinical Development
China-based HighTide Therapeutics Inc. has announced plans to make an initial public offering (IPO) on...
Shanghai Duoning Biotechnology Partners with Wuhan Kaide Jinuo for Gene Therapy R&D
China’s Shanghai Duoning Biotechnology Co., Ltd has announced a strategic licensing deal with compatriot firm...
Guangdong Zhongsheng Pharma Initiates Phase IIb Study for ZSP1601 in NASH
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced the first subject enrollment in...
Novartis’s Iptacopan on Track for Priority Review Status in China for PNH Treatment
China’s Center for Drug Evaluation (CDE) website has indicated that Swiss pharmaceutical giant Novartis’ (NYSE:...
CSPC Pharmaceutical Group Partners with China Unicom for Digital Transformation
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced a strategic partnership with Chinese mobile...
Novo Nordisk’s Semaglutide for Weight Loss Accepted for Review by China’s NMPA
Denmark-headquartered Novo Nordisk (NYSE: NVO) has announced that its market filing for the glucagon-like peptide-1...
Qilu Pharmaceutical Gains Temporary FDA Approval to Import Cisplatin Amid US Shortage
Qilu Pharmaceutical, a China-based firm, has benefited from the effects of drug shortages in the...
CDE Releases 70th Batch of Generic Reference Preparations for Public Feedback
The Center for Drug Evaluation (CDE) has released the 70th batch of chemical generic reference...
CStone Pharmaceuticals and Blueprint Medicines’ Ayvakit Wins FDA Approval for ISM Treatment
Partners CStone Pharmaceuticals (HKG: 2616) and Blueprint Medicines have announced that the US FDA has...
Neurophth Biotechnology Partners with Sinopharm Group to Commercialize Gene Therapy NFS-01
China-based gene therapy specialist Neurophth Biotechnology Ltd has announced a strategic partnership with compatriot firm...